Cite
HARVARD Citation
Van Steenbergen, S. et al. (2017). Dose de‐escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case–control study. Alimentary pharmacology & therapeutics. 45 (7), pp. 923-932. [Online].